![Steven Hoerter](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Steven Hoerter
Directeur Général chez
MBX BIOSCIENCES, INC.
Fortune : 2 M $ au 30/06/2026
Profil
Steven L.
Hoerter currently serves as Chairman, President & Chief Executive Officer at MBX Biosciences, Inc. since 2026.
He is an Independent Director at Oric Pharmaceuticals, Inc. since 2021 and at C4 Therapeutics, Inc. since 2024.
He is also a Director at Yarrow Bioscience, Inc. Formerly, Mr. Hoerter was President, Chief Executive Officer & Director at Deciphera Pharmaceuticals, Inc. from 2019 to 2024 and held the same titles at Deciphera Pharmaceuticals LLC.
He was Director-Pipeline Development at Genentech, Inc. from 2005 to 2010.
He served as Independent Director at Constellation Pharmaceuticals, Inc. from 2016 to 2018 and again from 2018 to 2021.
He was Independent Director at Ignyta, Inc. from 2016 to 2018.
He was Chief Commercial Officer at Agios Pharmaceuticals, Inc. from 2016 to 2019.
He held the position of GM, Head-Sub-Saharan Africa & Indian Ocean Region at Roche Group.
He was Chief Commercial Officer & Executive VP at Clovis Oncology, Inc. from 2015 to 2016.
Mr. Hoerter earned an MBA from the University of Tilburg, completed undergraduate studies at Bucknell University, and completed graduate studies at the Krannert School of Management.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
MBX BIOSCIENCES, INC. 0,07 % | 04/06/2026 | 31 938 ( 0,07 % ) | 2 M $ | 30/06/2026 |
| 24/06/2026 | 0 ( -.--% ) | - $ | 30/06/2026 | |
| 31/03/2026 | 0 ( -.--% ) | - $ | 30/06/2026 |
Postes actifs de Steven Hoerter
| Sociétés | Poste | Début |
|---|---|---|
| ORIC PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 13/08/2021 |
| C4 THERAPEUTICS, INC. | Directeur/Membre du Conseil | 19/11/2024 |
| MBX BIOSCIENCES, INC. | Directeur Général | 13/07/2026 |
Anciens postes connus de Steven Hoerter
| Sociétés | Poste | Fin |
|---|---|---|
| DECIPHERA PHARMACEUTICALS, INC. | Directeur Général | 01/10/2024 |
| CONSTELLATION PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 15/07/2021 |
| AGIOS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/03/2019 |
| IGNYTA INC | Directeur/Membre du Conseil | 07/02/2018 |
| CONSTELLATION PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 01/02/2018 |
Formation de Steven Hoerter
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
50
Relations au 1er degré
14
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 14 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Agios Pharmaceuticals, Inc.
 Agios Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops therapeutics | Health Technology |
Roche Group
 Roche Group Real Estate DevelopmentFinance Manages real estate properties | Finance |
University of Tilburg
 University of Tilburg Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bucknell University
 Bucknell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel drugs targeting regulators of epigenetic function | Health Technology |
Deciphera Pharmaceuticals LLC
 Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Discovers and develops pharmaceutical preparations | Health Technology |
Clovis Oncology, Inc.
 Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as an biopharmaceutical company that acquires, develops and commercializes innovative anti cancer agents | Health Technology |
Ignyta, Inc.
 Ignyta, Inc. BiotechnologyHealth Technology Operates as a medicine biotechnology company which provides new drugs services for cancer patients | Health Technology |
Krannert School of Management
 Krannert School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Oric Pharmaceuticals, Inc.
 Oric Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops pharmaceutical products | Health Technology |
C4 Therapeutics, Inc.
 C4 Therapeutics, Inc. BiotechnologyHealth Technology Develops targeted protein degradation therapeutics for the treatment of cancer | Health Technology |
Deciphera Pharmaceuticals, Inc.
 Deciphera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops novel drug candidates to improve the lives of cancer patients | Health Technology |
MBX Biosciences, Inc.
 MBX Biosciences, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company focused on discovery and development of novel precision peptide therapies for endocrine & metabolic disorders | Health Technology |
